Five thousand pediatric-only rare conditions, or “orphan diseases,” lack a market large enough to drive intervention. American universities can change that by serving as a development force to conduct research in therapeutics and biomedical technologies for children.
Subscribe to:
Post Comments (Atom)
< + > Stop Waiting on Mandates: CMS Challenges Health IT to Act Now
“We’re the government and we’re here to help.” That’s a common punchline, but based on recent IT announcements from CMS, this line may turn ...
No comments:
Post a Comment